Centrally Active Ghrelin Agonist for Blood-Brain Barrier Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing small molecule ghrelin agonists face challenges in efficiently permeating the blood-brain barrier, achieving balanced pharmacokinetic distribution between central and peripheral compartments, and maintaining therapeutic efficacy while minimizing brain accumulation, which limits their clinical utility in neurological and cardiovascular conditions.
Innovation Solution
The compound 3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea monohydrochloride salt acts as a ghrelin agonist with high blood-brain barrier permeability, displaying neuroprotective and bradycardic effects, and exhibits a non-linear dose-response, allowing effective treatment of neurological and cardiovascular conditions without excessive brain accumulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ghrelin peptide is administered to achieve therapeutic effects in the central nervous system, then neuroprotective and appetite-regulating activities are improved, but brain penetration is limited and half-life is short
Solution Approach 1:
The patent changes the chemical parameters by developing non-peptide small molecule agonists with modified molecular structure, lipophilicity, and metabolic stability. These parameter changes enable the compounds to achieve longer half-lives (e.g., compound 1 with half-life >24 hours) while maintaining or enhancing CNS penetration and ghrelin receptor affinity, directly resolving the contradiction between therapeutic efficacy and duration of action
Solution Approach 2:
The patent replaces the short-lived ghrelin peptide with stable small molecule compounds that act as disposable therapeutic agents. These molecules are designed to be metabolically stable and resistant to degradation, providing sustained therapeutic effects without requiring continuous administration, thus overcoming the limitations of the original peptide's short half-life
2Reliability
If small molecule ghrelin agonists are designed to improve brain penetration, then central nervous system activity is enhanced, but brain accumulation increases which may cause toxicity
Solution Approach 1:
The patent optimizes the lipophilicity parameter (logP) of the small molecule agonists to achieve balanced brain penetration. By carefully tuning this parameter, the compounds can cross the blood-brain barrier effectively to reach therapeutic concentrations in the CNS while avoiding excessive accumulation that would lead to toxicity, thus resolving the contradiction between CNS activity and safety
Solution Approach 2:
The patent employs in vivo microdialysis and other monitoring techniques to measure actual brain concentrations of the agonists in real-time. This feedback information is used to optimize the molecular structure and dosing regimen, ensuring that brain levels remain within the therapeutic window - high enough to be effective but low enough to avoid accumulation-related toxicity
3Reliability
If ghrelin agonists are administered to achieve therapeutic effects, then neuroprotective activity is improved, but pharmacokinetic distribution between central and peripheral compartments is unbalanced
Solution Approach 1:
The patent modifies the molecular parameters of the agonists to achieve optimal pharmacokinetic distribution. By adjusting properties such as molecular weight, lipophilicity, and plasma protein binding, the compounds are designed to maintain appropriate concentration ratios between central and peripheral compartments, ensuring sufficient CNS penetration for neuroprotection while maintaining therapeutic levels in peripheral tissues
Data Source
AI summary
The new compound 3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea monohydrochloride salt has a high capability to permeate through the blood-brain barrier and to display, at central nervous system level, a consistent ghrelin agonist activity; the compound is effective in the treatment and/or prevention of a medical condition mediated by the ghrelin receptor in the central nervous system. In particular, in experimental tests, the compound has shown high efficacy in the treatment of neurotoxic damage, with a useful combined pattern of neuroprotective effects both at central and peripheral level. The compound is further useful in the treatment of conditions which require a reduction of the heart rate. The compound is pharmacologically active at low to moderate doses, thus showing a favourable therapeutic index.